Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study involves people with schizophrenia or schizoaffective disorder, who are currently
taking antipsychotic medications. Some antipsychotic medications may cause an increase in
cholesterol levels, which may lead to inflammation in the body. Inflammation poses a risk in
developing heart disease, diabetes and problems with brain function. The purpose of this
study is to see if pravastatin can:
- Lower cholesterol
- Decrease inflammation
- Improve cognition in patients with schizophrenia
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
North Suffolk Mental Health Association Stanley Medical Research Institute